Producer
Copan Diagnostics / Copan Group
Brescia, Lombardy-based manufacturer that invented and patented flocked nasopharyngeal swab technology (FLOQSwab, 2003). Pre-COVID held ~50% of global NP swab supply. Located in the Lombardy region — the first European COVID epicenter — creating a catastrophic supply chain disruption when their workers were among the first hospitalized.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input Copan Diagnostics / Copan Group supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Copan Diagnostics / Copan Group makes, pick one to see the full supply chain.
Where they make it
2 facilities
Copan Group Brescia Facility →
ITmanufacturing
Primary global NP swab manufacturing. Located in Lombardy, Italy — the first European COVID-19 hotspot (February-March 2020), directly disrupting global swab supply at the moment of peak demand.
Copan USA Murrieta California Manufacturing →
USCalifornia · processing
Copan US production facility opened post-COVID to serve Americas market; supplements Brescia Italy capacity; reduces single-country (Italy) production dependency; part of Copan's capacity expansion from ~100M to 1B swabs/year
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
FLOQSwab® Flocked Nasopharyngeal & Specimen Swabs
55%Transport Media (UTM / VTM / ESwab)
25%WASPLab® Automated Microbiology (Robotics)
15%Specialty Diagnostics & Forensics
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Origin2020
Copan invented the flocked nasopharyngeal swab in 2003 — the first swab manufactured using electrostatic flocking to deposit perpendicular nylon fibers that dramatically improve specimen collection and elution compared to traditional wound-fiber swabs. Copan's FLOQSwabs are CDC-recommended and patent-protected, creating a regulatory and IP lock-in that prevented emergency entry by new manufacturers during the 2020 crisis. Even hospitals desperate for swabs could not legally manufacture or import substitutes without FDA emergency authorization. Revenue went from ~$100M pre-COVID to $372M in 2020 and $445M in 2021 as Copan quintupled profits.
PR Newswire / Copan Group ↗Did you know2023
Copan Diagnostics — the medical swab company — also built WASPLab®, one of the world's most advanced fully automated clinical microbiology systems. WASPLab automates the entire workflow from specimen receipt to culture reading: robotic specimen processors streak plates automatically, automated incubators track culture growth, and AI image analysis (TIRAMISU platform) reads culture plates for colonies, pathogen morphology, and antibiotic sensitivity. A company best known for the cotton (actually nylon flock) swabs nurses insert into patients' noses is simultaneously a leader in laboratory robotics and AI-assisted clinical microbiology. The same Italian family company in Brescia that invented the pandemic testing swab also invented the robot that reads the culture plates your swab is streaked onto.
Copan Group ↗Capacity2020
Copan's Brescia factory — which held ~50% of global NP swab supply — was inside the Lombardy province, the first and worst-hit COVID epicenter in Europe. In February-March 2020, Copan workers were among the first Italians hospitalized with COVID-19. The factory continued operating through the Italian lockdown under emergency protocols, but with reduced staffing. The FDA, CDC, and HHS were simultaneously trying to scale up COVID testing while the dominant NP swab manufacturer was in a COVID hotspot. This single geographic coincidence — a critical supply chain node located inside the first Western pandemic epicenter — threatened to eliminate testing capacity at exactly the moment maximum testing was needed. The supply crisis prompted both US government and EU emergency orders to Copan, and also triggered FEMA and HHS investments in US-domestic NP swab manufacturing alternatives.
The New York Times ↗